MiMedx Group, Inc. (NASDAQ:MDXG) Holdings Decreased by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. decreased its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 24.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,393 shares of the company’s stock after selling 3,392 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in MiMedx Group were worth $91,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. SG Americas Securities LLC acquired a new stake in MiMedx Group during the third quarter valued at $289,000. Robeco Institutional Asset Management B.V. acquired a new stake in MiMedx Group during the third quarter valued at $74,000. Bank of New York Mellon Corp boosted its position in MiMedx Group by 7.1% during the third quarter. Bank of New York Mellon Corp now owns 424,221 shares of the company’s stock valued at $3,093,000 after purchasing an additional 28,305 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in MiMedx Group by 97.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,066 shares of the company’s stock valued at $219,000 after purchasing an additional 14,862 shares during the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in MiMedx Group during the third quarter valued at $88,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Insider Buying and Selling

In related news, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total transaction of $122,320.71. Following the completion of the transaction, the chief operating officer now owns 401,050 shares of the company’s stock, valued at approximately $3,212,410.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Ricci S. Whitlow sold 15,493 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $8.07, for a total transaction of $125,028.51. Following the completion of the transaction, the chief operating officer now owns 416,321 shares of the company’s stock, valued at approximately $3,359,710.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the transaction, the chief operating officer now directly owns 401,050 shares of the company’s stock, valued at approximately $3,212,410.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,145 shares of company stock valued at $409,378. Insiders own 19.90% of the company’s stock.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $6.25 on Friday. MiMedx Group, Inc. has a fifty-two week low of $3.49 and a fifty-two week high of $9.27. The business has a 50-day moving average of $7.50 and a two-hundred day moving average of $7.56. The stock has a market capitalization of $917.77 million, a P/E ratio of 19.52 and a beta of 1.32. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). MiMedx Group had a return on equity of 41.12% and a net margin of 14.49%. The company had revenue of $86.83 million during the quarter, compared to analyst estimates of $85.58 million. On average, equities research analysts predict that MiMedx Group, Inc. will post 0.33 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on MDXG shares. Mizuho lifted their price objective on MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Lake Street Capital initiated coverage on MiMedx Group in a research report on Thursday, March 7th. They set a “buy” rating and a $12.00 price objective for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.25.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.